These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7727540)

  • 1. Further studies of the in vitro activity of synthetic gliadin peptides in coeliac disease.
    Cornell H; Mothes T
    Biochim Biophys Acta; 1995 Apr; 1270(2-3):168-72. PubMed ID: 7727540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activity of wheat gliadin peptides in in vitro assays for coeliac disease.
    Cornell HJ; Mothes T
    Biochim Biophys Acta; 1993 Apr; 1181(2):169-73. PubMed ID: 8481406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural specificities and significance for coeliac disease of wheat gliadin peptides able to agglutinate or to prevent agglutination of K562(S) cells.
    De Vincenzi M; Stammati A; Luchetti R; Silano M; Gasbarrini G; Silano V
    Toxicology; 1998 May; 127(1-3):97-106. PubMed ID: 9699797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between gliadin peptide structure and their effect on the fetal chick duodenum.
    Kocna P; Mothes T; Krchnák V; Fric P
    Z Lebensm Unters Forsch; 1991 Feb; 192(2):116-9. PubMed ID: 2014713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing one of the DQ2 candidate epitopes in coeliac disease: A-gliadin 51-70 toxicity assessed using an organ culture system.
    Martucci S; Fraser JS; Biagi F; Corazza GR; Ciclitira PJ; Ellis HJ
    Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1293-8. PubMed ID: 14624152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of A-gliadin-related synthetic peptides: damaging effect on the atrophic coeliac mucosa and activation of mucosal immune response in the treated coeliac mucosa.
    Maiuri L; Troncone R; Mayer M; Coletta S; Picarelli A; De Vincenzi M; Pavone V; Auricchio S
    Scand J Gastroenterol; 1996 Mar; 31(3):247-53. PubMed ID: 8833354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro mucosal digestion of synthetic gliadin-derived peptides in celiac disease.
    Cornell HJ; Rivett DE
    J Protein Chem; 1995 Jul; 14(5):335-9. PubMed ID: 8590601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous-flow synthesis of alpha-gliadin peptides in an ultrasonic field and assay of their inhibition of intestinal sucrase activity.
    Vágner J; Kocna P; Krchnák V
    Pept Res; 1991; 4(5):284-8. PubMed ID: 1839365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro (organ culture) studies of the toxicity of specific A-gliadin peptides in celiac disease.
    de Ritis G; Auricchio S; Jones HW; Lew EJ; Bernardin JE; Kasarda DD
    Gastroenterology; 1988 Jan; 94(1):41-9. PubMed ID: 3335296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial in vitro digestion of active gliadin-related peptides in celiac disease.
    Cornell HJ
    J Protein Chem; 1998 Nov; 17(8):739-44. PubMed ID: 9988520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of gliadin peptides on rat-liver lysosomes in relation to the pathogenesis of coeliac disease.
    Cornell HJ; Townley RR
    Clin Chim Acta; 1973 Dec; 49(2):181-8. PubMed ID: 4589526
    [No Abstract]   [Full Text] [Related]  

  • 12. Wheat peptide challenge in coeliac disease.
    Sturgess R; Day P; Ellis HJ; Lundin KE; Gjertsen HA; Kontakou M; Ciclitira PJ
    Lancet; 1994 Mar; 343(8900):758-61. PubMed ID: 7907731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amino acid composition of gliadin fractions which may be toxic to individuals with coeliac disease.
    Cornell HJ; Maxwell RJ
    Clin Chim Acta; 1982 Aug; 123(3):311-9. PubMed ID: 6811164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the gliadin-derived peptides which are biologically active in coeliac disease.
    Cornell H; Wieser H; Belitz HD
    Clin Chim Acta; 1992 Dec; 213(1-3):37-50. PubMed ID: 1477986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysosomal damage by gliadin and gliadin peptides; an activity not related to coeliac disease.
    de Rooij FW; van den Aarsen CP; Hekkens WT
    Clin Chim Acta; 1979 Jan; 91(2):127-31. PubMed ID: 759040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amino acid composition of peptides remaining after in vitro digestion of a gliadin sub-fraction with duodenal mucosa from patients with coeliac disease.
    Cornell HJ
    Clin Chim Acta; 1988 Sep; 176(3):279-89. PubMed ID: 3180479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships in coeliac-toxic gliadin peptides.
    Cornell HJ; Wills-Johnson G
    Amino Acids; 2001; 21(3):243-53. PubMed ID: 11764405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of in vitro gamma-interferon production in coeliac disease as a response to gliadin peptides.
    Cornell HJ; Skerritt JH; Puy R; Javadpour M
    Biochim Biophys Acta; 1994 May; 1226(2):126-30. PubMed ID: 8204658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agglutinating activity of wheat gliadin peptide fractions in coeliac disease.
    De Vincenzi M; Dessi MR; Giovannini C; Maialetti F; Mancini E
    Toxicology; 1995 Jan; 96(1):29-35. PubMed ID: 7863509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of extended amino acid motifs for focussing on toxic peptides in coeliac disease.
    McLachlan A; Cullis PG; Cornell HJ
    J Biochem Mol Biol Biophys; 2002 Oct; 6(5):319-24. PubMed ID: 12385967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.